ACTA FARMACEUTICA BONAERENSE, cilt.40, sa.12, ss.2920-2926, 2021 (SCI-Expanded)
Ketamine is a short-acting anesthetic drug that is derived from phencyclidine. Ketamine is
used to treat depression and chronic pain disorders, as well as for anesthesia, analgesia, and sedation. Ketamine’s sympathomimetic characteristic causes cardiotoxicity. The pathophysiology of ketamine’s harmful
impact has been linked to reactive oxygen species (ROS) and proinflammatory cytokines such as interleukin
1 beta (IL-1), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α). Tianeptine is an antidepressant
that works similarly to tricyclic antidepressants. According to studies, tianeptine reduces the production of
proinflammatory cytokines such as ROS, IL-1, IL-6, and TNF-α. Tianeptine has a sympatholytic action as
well. All of this evidence suggests that tianeptine might help to reduce ketamine cardiotoxicity. The goal of
our research is to use biochemical and histological techniques to see how tianeptine affects ketamine-induced
cardiotoxicity in rats.